News AstraZeneca reveals $570m investment in Canada AstraZeneca has announced another major investment in Canada, tapping into the country's emergence as a "global hub" for clinical trials.
News EU approves endometrial, lung cancer drugs from GSK and J&J Both GSK and J&J have claimed pivotal approvals for growth-phase oncology therapies in the EU.
News AZ, Daiichi get FDA nod for Dato-DXd in breast cancer AstraZeneca and Daiichi Sankyo have claimed FDA approval for a second antibody-drug conjugate for breast cancer - TROP2-directed Datroway.
News Amgen picks up key colorectal cancer okay for KRAS drug Can a new FDA approval in colorectal cancer kickstart sales growth for Amgen's KRAS inhibitor Lumakras?
News Kardigan raises $300m for cardio work, and other financings Kardigan makes its debut with a teal of ex-MyoKardia execs and a $300m war chest, with a string of other biotechs also raising funds this week.
News AZ's Calquence gets first-line OK in mantle cell lymphoma AstraZeneca's BTK inhibitor Calquence is the first drug in the class to be approved in the US for first-line treatment of mantle cell lymphoma.
News Allergy Tx plots grass pollen jab launch after German okay Allergy Therapeutics has had its grass pollen allergy treatment Grassmuno approved in Germany, its first market, setting up a launch early next year.
Sales & Marketing Sponsored The AI imperative: Establishing the standard for modern clin... The findings from the Medidata-commissioned survey confirm that AI implementation in clinical trials has moved firmly beyond theoretical discussion.